Mercedes Segura Gally

home / authors / mercedes-segura-gally

Mercedes Segura Gally is vice-president of Vector Process Development at ElevateBio.

Articles

David Crockett/Stock.Adobe.com – Rapid growth in cell-based immuno-oncology pipelines and early development efforts with in-vivo lentiviral vector-based therapies are fueling CGT growth.

Tactics and Strategies for Designing an Ideal Lentiviral Vector Platform

Bojiao Yin;Mercedes Segura Gally;Jimmy Xin;James Fasano

There is growing pressure for robust and economically scalable viral-vector manufacturing technologies.

Latest Updated Articles

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

Published: September 11th 2024 | Updated: September 18th 2024

CPHI Pharma Award Finalists Announced for 2024

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Published: March 27th 2024 | Updated: June 28th 2024

AbbVie Acquires Landos Biopharma and Gets Full FDA Nod for ADC Product

Published: November 15th 2024 | Updated: November 20th 2024

Solving Challenges with AAV Aggregate Analysis Using a Novel Size Exclusion Particle to Determine CQAs

Published: October 28th 2024 | Updated: November 20th 2024

Cell-based phenotypic screening with Incucyte® Live-Cell Analysis Systems

Optimizing cGMP Facility Design Space with a Hybrid Approach

Published: October 22nd 2024 | Updated: November 20th 2024

Optimizing cGMP Facility Design Space with a Hybrid Approach

Published: October 28th 2024 | Updated: November 20th 2024

Quantifying Chemotherapeutic Cytotoxicity in Glial Cells using AI-Driven Label-Free Cell Analysis

Editorial Information

Do Not Sell My Personal Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.